2014 Lung Cancer Research Foundation Annual Grant Program
Donald Kufe, MD
Dana-Farber Cancer Institute
Research Project:
Development of New Therapeutic Agents for NSCLC Resistant to Existing Therapies
Summary:
Dr. Kufe and his team will further develop new NUCI-C inhibitors for effectiveness against NSCLC cells with EGFR or KRAS mutations growing in vitro and in animal models. The first-in-man MUCI-C inhibitor has completed Phase I of evaluation in patients with refractory solid tumors and, based on those results, this study will be positioned to further develop the next generation of these inhibitors alone and in combination for the treatment of patients with refractory NSCLC.
This project has received multiple year funding.